A clnical trIal comparing the effect of treatment with oral spironolactone compared with a placebo on the frequency and duration of atrIal fibrillation in patients with an implanted cardiac device in New Zealand.
Phase 4
- Conditions
- Atrial FibrillationCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12616001188426
- Lead Sponsor
- niversity of Otago
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Patients with an implanted cardiac device capable of recording the frequency and duration of AF events and with
evidence of AF or AHRE within the 6months
prior to recruitment will be eligible.
age >18 years (without childbearing
potential for women); with an implantable device capable of
AF or AHRE monitoring; and with device documented AF or AHRE (defined as AHRE >220 bpm for >2% of the time
or for > 5mins on at least one occasion) in the last 6months.
Exclusion Criteria
Permanent AF,
Receiving AF suppression pacing
History of heart failure with indication for MRAs
A clinical indication for MRA or K+ sparing diuretic
Contraindication to MRA
Severe renal dysfunction
Sustained hyperkalaemia in the absence of reversible cause
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method